EUVIMEDEUVIMED entdecken
Leserbrief

Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab

J O Gordilho iD, D Miyamoto, C W Maruta, R M Santo, A Mahmoud, T Navarro-Rodriguez, A L Werneck-Silva, L M de Aguiar, I C Borges, C G Santi, V Aoki iD

Journal of the European Academy of Dermatology and Venereology · 2024

DOI: 10.1111/jdv.19413 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von J O Gordilho und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Rituximab. Die Arbeit nennt 10 Literaturangaben. Gefördert von: CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), FUNADERSP (Fundo de Apoio à Dermatologia do Estado de São Paulo), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epidermolysis BullosaEpidermolysis Bullosa AcquisitaRituximabHumansImmunoglobulin G

Substanzen

Immunoglobulin GRituximab

Autor:innen und Institutionen

  • Department of Dermatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.
  • Department of Ophthalmology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.
  • Department of Otorhinolaryngology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.
  • Department of Gastroenterology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.
  • Department of Ginecology, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.
  • Department of Infectious Diseases, Faculdade de Medicina FMUSP, Universidade de São Paulo, Sao Paulo, SP, Brazil.

ORCID-Profile: J O Gordilho, V Aoki

Förderung

  • CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior)
  • FUNADERSP (Fundo de Apoio à Dermatologia do Estado de São Paulo)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Gordilho, J. O., Miyamoto, D., Maruta, C. W., Santo, R. M., Mahmoud, A., Navarro-Rodriguez, T., Werneck-Silva, A. L., de Aguiar, L. M., Borges, I. C., Santi, C. G., & Aoki, V. (2024). Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19413

Vancouver

Gordilho JO, Miyamoto D, Maruta CW, Santo RM, Mahmoud A, Navarro-Rodriguez T, et al. Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19413

BibTeX
@article{Gordilho2024,
  author = {Gordilho, J O and Miyamoto, D and Maruta, C W and Santo, R M and Mahmoud, A and Navarro-Rodriguez, T and Werneck-Silva, A L and de Aguiar, L M and Borges, I C and Santi, C G and Aoki, V},
  title = {Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  doi = {10.1111/jdv.19413}
}
Kostenlos starten →